A number of investment brokers have recently updated their price targets on shares of BioTelemetry, Inc. (NASDAQ:BEAT). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

07/28/2015 – BioTelemetry, Inc. had its “buy” rating reiterated by analysts at Dougherty & Co. They now have a USD 20 price target on the stock.

03/04/2015 – BioTelemetry, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 11.6 price target on the stock.

12/04/2014 – BioTelemetry, Inc. had its “buy” rating reiterated by analysts at Benchmark. They now have a USD 18 price target on the stock.

11/24/2014 – BioTelemetry, Inc. was upgraded to “outperform” by analysts at Avondale Partners.

06/03/2014 – BioTelemetry, Inc. was downgraded to “sell” by analysts at TheStreet.

The share price of BioTelemetry, Inc. (NASDAQ:BEAT) was down -1.44% during the last day of trading, with a day high of 15.60. 201405 shares were traded during the last session.

The stock’s 50 day moving average is 12.56 and its 200 day moving average is 12.04. The stock’s market capitalization is 413.83M. BioTelemetry, Inc. has a 52-week low of 8.74 and a 52-week high of 16.96.

View other investors thoughts on BioTelemetry, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.